SCHEMBL6569124

SCHEMBL6569124

COc1cccc(C(=O)NN=Cc2ccccc2O)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 3/20 0.67
TP53 P04637 1/20 0.64
TSHR P16473 1/20 0.64
KMT2A Q03164 5/20 0.63
HTT P42858 3/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
LMNA P02545 2/20 0.63
KDM4E B2RXH2 1/20 0.63
POLB P06746 1/20 0.63
PTBP1 P26599 1/20 0.63
TDP1 Q9NUW8 1/20 0.63
DUSP3 P51452 1/20 0.62
PTPN5 P54829 1/20 0.62
PTPN11 Q06124 1/20 0.62
MAPT P10636 2/20 0.60
MAOA P21397 1/20 0.60
MAOB P27338 1/20 0.60
NPC1 O15118 5/20 0.59
RAB9A P51151 3/20 0.59
MEN1 O00255 3/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6569120 1.00 KDM1A (0.67) KDM1ATP53TSHRKMT2AHTT
SCHEMBL6571534 0.88 NPC1 (0.59) KDM1AKMT2AHTTSMN1; SMN2LMNA
SCHEMBL6571538 0.88 NPC1 (0.59) KDM1AKMT2AHTTSMN1; SMN2LMNA
SCHEMBL684539 0.86 KMT2A (0.71) KMT2AHTTSMN1; SMN2LMNAKDM4E
SCHEMBL684843 0.86 KDM1A (0.63) KDM1AKMT2AHTTSMN1; SMN2LMNA
SCHEMBL28426747 0.85 MAPT (0.60) KMT2ASMN1; SMN2KDM4EPOLBMAPT
SCHEMBL28029715 0.85 KDM1A (0.71) KDM1ATP53KMT2AHTTSMN1; SMN2
SCHEMBL683806 0.84 GAA (0.65) KMT2AHTTSMN1; SMN2LMNAKDM4E
SCHEMBL683790 0.84 MGAM (0.66) KDM1AKMT2ASMN1; SMN2LMNAKDM4E
SCHEMBL684835 0.83 KDM1A (0.72) KDM1ATP53KMT2AHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US claimed
US-20040110963-A1 Novel hydrazones ARPIDA AG (CH) 2004-06-10 US disclosed
EP-1404644-A2 NOVEL HYDRAZONES Arpida AG, (CH) 2004-04-07 EP disclosed
WO-2002070464-A2 HYDRAZONES AND THEIR THERAPEUTIC USE ARPIDA AG (CH) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110963-A1 Novel hydrazones H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK1, MPO KDM1A 2684/4885TP53 3905/4885TSHR 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.